Lincoln (LINCOLN) | Financial Analysis & Statements
Lincoln Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.5B
Gross Profit
846.8M
54.96%
Operating Income
203.3M
13.19%
Net Income
276.8M
17.96%
EPS (Diluted)
₹13.82
Balance Sheet Metrics
Total Assets
8.0B
Total Liabilities
1.3B
Shareholders Equity
6.7B
Debt to Equity
0.19
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Lincoln Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.2B | 5.7B | 5.0B | 4.7B | 4.1B |
| Cost of Goods Sold | 2.9B | 2.8B | 2.4B | 2.2B | 2.0B |
| Gross Profit | 3.2B | 2.9B | 2.6B | 2.5B | 2.2B |
| Gross Margin % | 52.4% | 51.0% | 51.9% | 53.1% | 52.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 528.9M | 412.5M | 379.5M | 354.4M | 349.1M |
| Other Operating Expenses | 436.2M | 399.6M | 345.3M | 295.7M | 298.3M |
| Total Operating Expenses | 965.2M | 812.1M | 724.8M | 650.2M | 647.4M |
| Operating Income | 892.1M | 896.2M | 806.8M | 884.0M | 798.0M |
| Operating Margin % | 14.5% | 15.7% | 16.0% | 18.9% | 19.2% |
| Non-Operating Items | |||||
| Interest Income | 72.2M | 70.2M | 61.7M | 50.3M | 22.4M |
| Interest Expense | 10.0M | 9.5M | 16.4M | 9.2M | 12.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.1B | 1.2B | 1.0B | 959.4M | 837.2M |
| Income Tax | 268.4M | 289.4M | 275.8M | 265.8M | 214.7M |
| Effective Tax Rate % | 24.6% | 23.7% | 27.4% | 27.7% | 25.6% |
| Net Income | 823.5M | 933.0M | 729.0M | 693.6M | 622.5M |
| Net Margin % | 13.4% | 16.3% | 14.4% | 14.8% | 15.0% |
| Key Metrics | |||||
| EBITDA | 1.2B | 1.1B | 1.1B | 1.0B | 896.9M |
| EPS (Basic) | ₹41.11 | ₹46.58 | ₹36.40 | ₹34.63 | ₹31.08 |
| EPS (Diluted) | ₹41.11 | ₹46.58 | ₹36.40 | ₹34.63 | ₹31.08 |
| Basic Shares Outstanding | 20029728 | 20029728 | 20029728 | 20029728 | 20029728 |
| Diluted Shares Outstanding | 20029728 | 20029728 | 20029728 | 20029728 | 20029728 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Lincoln Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 134.1M | 57.5M | 50.5M | 69.3M | 114.4M |
| Short-term Investments | 1.8B | 1.5B | 1.1B | 1.1B | 806.7M |
| Accounts Receivable | 1.7B | 1.6B | 1.4B | 1.2B | 1.1B |
| Inventory | 786.8M | 771.7M | 700.3M | 727.4M | 466.1M |
| Other Current Assets | 215.6M | 161.1M | 113.0M | 159.6M | 13.0K |
| Total Current Assets | 5.0B | 4.5B | 3.7B | 3.5B | 3.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 220.8M | 218.1M | 53.7M | 42.1M | 30.5M |
| Goodwill | 4.4M | 3.3M | 2.9M | 3.8M | 96.2M |
| Intangible Assets | 4.4M | 3.3M | 2.9M | 3.8M | 4.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | 1.0K | 2.0K | 45.8M | 9.0K |
| Total Non-Current Assets | 3.0B | 2.5B | 2.2B | 1.8B | 1.4B |
| Total Assets | 8.0B | 7.0B | 5.9B | 5.3B | 4.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 849.5M | 724.4M | 508.7M | 716.7M | 570.7M |
| Short-term Debt | - | 10.7M | 20.0M | 20.4M | 3.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 51.2M | 27.4M | 20.9M | 12.3M | 10.0M |
| Total Current Liabilities | 1.1B | 922.8M | 721.5M | 904.9M | 758.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | 0 | 1.4M |
| Deferred Tax Liabilities | 130.0M | 114.6M | 79.4M | 64.5M | 56.9M |
| Other Non-Current Liabilities | - | - | 1.0K | 1.0K | -3.0K |
| Total Non-Current Liabilities | 191.2M | 151.8M | 128.0M | 109.9M | 101.3M |
| Total Liabilities | 1.3B | 1.1B | 849.5M | 1.0B | 859.7M |
| Equity | |||||
| Common Stock | 200.3M | 200.3M | 200.3M | 200.3M | 200.3M |
| Retained Earnings | 5.9B | 5.1B | 4.2B | 3.5B | 2.8B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.7B | 5.9B | 5.0B | 4.3B | 3.7B |
| Key Metrics | |||||
| Total Debt | 0 | 10.7M | 20.0M | 20.4M | 5.2M |
| Working Capital | 3.9B | 3.5B | 3.0B | 2.6B | 2.3B |
Balance Sheet Composition
Lincoln Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.1B | 1.2B | 1.0B | 959.4M | 837.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -70.6M | -373.6M | -118.3M | -128.4M | -50.9M |
| Operating Cash Flow | 967.9M | 793.2M | 845.1M | 795.2M | 787.6M |
| Investing Activities | |||||
| Capital Expenditures | -189.1M | -393.9M | -135.5M | -454.5M | -86.9M |
| Acquisitions | - | - | - | 0 | 500.0K |
| Investment Purchases | -851.4M | -996.3M | -631.9M | -530.5M | -545.0M |
| Investment Sales | 564.5M | 748.3M | 738.0M | 405.2M | 105.0M |
| Investing Cash Flow | -488.4M | -426.4M | -179.6M | -687.3M | -530.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -36.1M | -30.0M | -30.0M | -30.0M | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -694.2M | -209.0M | -195.0M | -5.2M | -45.5M |
| Financing Cash Flow | -740.2M | -248.1M | -226.5M | -15.2M | -83.9M |
| Free Cash Flow | 737.7M | 236.0M | 249.8M | 306.1M | 605.2M |
| Net Change in Cash | -260.8M | 118.8M | 439.0M | 92.7M | 173.0M |
Cash Flow Trend
Lincoln Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
13.91
Price to Book
1.71
Price to Sales
1.87
PEG Ratio
0.37
Profitability Ratios
Profit Margin
13.47%
Operating Margin
11.95%
Return on Equity
12.26%
Return on Assets
10.33%
Financial Health
Current Ratio
4.71
Debt to Equity
0.01
Beta
0.36
Per Share Data
EPS (TTM)
₹43.85
Book Value per Share
₹357.45
Revenue per Share
₹325.49
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| LINCOLN | 12.2B | 13.91 | 1.71 | 12.26% | 13.47% | 0.01 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





